請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25073
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉宏輝 | |
dc.contributor.author | Ting-Shan Tsai | en |
dc.contributor.author | 蔡廷姍 | zh_TW |
dc.date.accessioned | 2021-06-08T06:01:39Z | - |
dc.date.copyright | 2007-08-08 | |
dc.date.issued | 2007 | |
dc.date.submitted | 2007-07-27 | |
dc.identifier.citation | Anderson NJ, Slough S, Watson WP. (2006). In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant.
Eur J Pharmacol 28, 48-53. Angehagen M, Rönnbäck L, Hansson E, Ben-Menachem E. (2005). Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem 94, 1124-30. Araújo DA, Mafra RA, Rodrigues AL, Miguel-Silva V, Beirão PS, de Almeida RN, Quintans L, de Souza MF, Cruz JS. (2003). N-salicyloyltryptamine, a new anticonvulsant drug, acts on voltage-dependent Na+, Ca2+, and K+ ion channels. Br J Pharmacol 140, 1331-9. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adin J. (2005). Ion channels and epilepsy. Curr Pharm Des 11, 1975-2003. Amoroso S, Schmid-Antomarchi H, Fosset M, Lazdunski M. (1990). Glucose, sulfonylureas, and neurotransmitter release: role of ATP-sensitive K+ channels. Science 247, 852-4. Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A, Traynelis SF. (2000). Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci 20, 89-102. Bauer J, Ben-Menachem E, Krämer G, Fryze W, Da Silva S, Kasteleijn-Nolst Trenité DG. (2006). Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand 114, 169-76. Béguin P, Nagashima K, Nishimura M, Gonoi T, Seino S. (1999). PKA-mediated phosphorylation of the human K(ATP) channel: separate roles of Kir6.2 and SUR1 subunit phosphorylation. EMBO J 18, 4722-32. Butt AM, Kalsi A. (2006). Inwardly rectifying potassium channels (Kir) in central nervous system glia: a special role for Kir4.1 in glial functions. J Cell Mol Med 10, 33-44. Carl GF, Smith ML. (1989). Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations. Epilepsia 30, 217-24. Carvalho AL, Kameyama K, Huganir RL. (1999). Characterization of phosphorylation sites on the glutamate receptor 4 subunit of the AMPA receptors. J Neurosci 19, 4748-54. Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C. (2007). Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia 48, 654-62. Choe H, Zhou H, Palmer LG, Sackin H. (1997). A conserved cytoplasmic region of ROMK modulates pH sensitivity, conductance, and gating. Am J Physiol 273, F516-29. Curia G, Aracri P, Sancini G, Mantegazza M, Avanzini G, Franceschetti S. (2004). Protein-kinase C-dependent phosphorylation inhibits the effect of the antiepileptic drug topiramate on the persistent fraction of sodium currents. Neuroscience 127, 63-8. Doheny HC, Ratnaraj N, Whittington MA, Jeffery JG, Patsalos PN. (1999). Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 34, 161-168. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, Falke C, Zarate CA, Manji HK. (2007). The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32, 793-802. Errington AC, Stohr T, Lees G. (2005). Voltage gated ion channels: targets for anticonvulsant drugs. Curr Top Med Chem 5, 15-30. Fakler B, Schultz JH, Yang J, Schulte U, Brandle U, Zenner HP, Jan LY, Ruppersberg JP. (1996). Identification of a titratable lysine residue that determines sensitivity of kidney potassium channels (ROMK) to intracellular pH. EMBO J 15, 4093-9. Fu J, Kirk KL. (2001). Cysteine substitutions reveal dual functions of the amino-terminal tail in cystic fibrosis transmembrane conductance regulator channel gating. J Biol Chem 276, 35660-35668. Gu Y, Huang LY. (2001). Gabapentin actions on N-methyl-D-aspartate receptor channels are protein kinase C-dependent. Pain 93, 85-92. Hamilton SE, Loose MD, Levey AI, Hille B, McKnight GS, Idzerda RL, Nathanson NM. (1997). Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizures activity in mice. Proc Natl Acad Sci U S A 94, 13311-13316. Haria M, Balfour JA. (1997). Levetiracetam. Drugs 7, 159-164 Hernandez-Sanchez C, Basile AS, Fedorova I, Arima H, Stannard B, Fernandez AM, Ito Y, LeRoith D. (2001). Mice transgenically overexpressing sulfonylurea receptor 1 in forebrain resist seizure induction and excitotoxic neuron death. Proc Natl Acad Sci U S A. 98, 3549-3554. Huang CL, Feng S, Hilgemann DW. (1998). Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature 391, 803-806. Huang CW, Huang CC, Wu SN. (2006). The opening effect of pregabalin on ATP-sensitive potassium channels in differentiated hippocampal neuron-derived H19-7 cells. Epilepsia 47, 720-726. Huang CW, Huang CC, Wu SN. (2007). Activation by zonisamide, a newer antiepileptic drug, of large-conductance calcium-activated potassium channel in differentiated hippocampal neuron-derived H19-7 cells. J Pharmacol Exp Ther 321, 98-106. Isomoto S, Kondo C, Kurachi Y. (1997). Inwardly rectifying potassium channels: their molecular heterogeneity and function. Jpn J Physiol 47, 11-39. Jiang C, Xu H, Cui N, Wu J. (2001). An alternative approach to the identification of respiratory central chemoreceptors in the brainstem. Respir Physiol 129, 141-157. Jarolimek W, Bäurle J, Misgeld U. (1998). Pore mutation in a G-protein-gated inwardly rectifying K+ channel subunit causes loss of K+-dependent inhibition in weaver hippocampus. J Neurosci 18, 4001-4007. Kelly MJ, Qiu J, Wagner EJ, Rønnekleiv OK. (2002). Rapid effects of estrogen on G protein-coupled receptor activation of potassium channels in the central nervous system (CNS). J Steroid Biochem Mol Biol 83, 187-193. Kofuji P, Newman EA. (2004). Potassium buffering in the central nervous system. Neuroscience 129, 1045-1056. Kondo C, Isomoto S, Matsumoto S, Yamada M, Horio Y, Yamashita S, Takemura-Kameda K, Matsuzawa Y, Kurachi Y. (1996). Cloning and functional expression of a novel isoform of ROMK inwardly rectifying ATP-dependent K+ channel, ROMK6 (Kir1.1f). FEBS Lett 399, 122-126. Krapivinsky G, Medina I, Eng L, Krapivinsky L, Yang Y, Clapham DE. (1998). A novel inward rectifier K+ channel with unique pore properties. Neuron 5, 995-1005. Kulangara K, Kropf M, Glauser L, Magnin S, Alberi S, Yersin A, Hirling H. (2007). Phosphorylation of glutamate receptor interacting protein 1 regulates surface expression of glutamate receptors. J Biol Chem 282, 2395-2404 Levitan IB. (1985). phorylation of ion channels.J Membr Biol 87, 177-190. Levitan IB. (1994). Modulation of ion channels by protein phosphorylation and dephosphorylation. Annu Rev Physiol 56, 193-212.. Leung YM, Zeng WZ, Liou HH, Solaro CR, Huang CL. (2000). Phosphatidylinositol 4,5-bisphosphate and intracellular pH regulate the ROMK1 potassium channel via separate but interrelated mechanisms. J Biol Chem 275, 10182-10189. Lin YF, Jan YN, Jan LY. (2000). Regulation of ATP-sensitive potassium channel function by protein kinase A-mediated phosphorylation in transfected HEK293 cells. EMBO J 19, 942-955. Liou HH, Zhou SS, Huang CL. (1999). Regulation of ROMK1 channel by protein kinase A via a phosphatidylinositol 4,5-bisphosphate-dependent mechanism. Proc Natl Acad Sci U S A 96, 5820-5825. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101, 9861-9866. MacGregor GG, Xu JZ, McNicholas CM, Giebisch G, Hebert SC. (1998). Partially active channels produced by PKA site mutation of the cloned renal K+ channel, ROMK2 (kir1.2). Am J Physiol 275, F415-422. Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, Speckmann EJ. (2003). Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 45, 661-671. Maneuf YP, McKnight AT. (2001). Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 134, 237-240. Martin SC, Bjork I. (1990). Conformational changes in human fibrinogen after in vitro phosphorylation and their relation to fibrinogen behaviour. FEBS Lett 15, 103-105. McNicholas CM, Wang W, Ho K, Hebert SC, Giebisch G. (1994). Regulation of ROMK1 K+ channel activity involves phosphorylation processes. Proc Natl Acad Sci U S A 91, 8077-8081. Müllner C, Vorobiov D, Bera AK, Uezono Y, Yakubovich D, Frohnwieser-Steinecker B, Dascal N, Schreibmayer W. (2000). Heterologous facilitation of G protein-activated K(+) channels by beta-adrenergic stimulation via cAMP-dependent protein kinase. J Gen Physiol 115, 547-558. Nadeau H, McKinney S, Anderson DJ, Lester HA. (2000). ROMK1 (Kir1.1) causes apoptosis and chronic silencing of hippocampal neurons.J Neurophysiol 84, 1062-1075. Neusch C, Weishaupt JH, Bähr M. (2003). Kir channels in the CNS: emerging new roles and implications for neurological diseases. Cell Tissue Res 311, 131-138. Niimura M, Moussa R, Bissoon N, Ikeda-Douglas C, Milgram NW, Gurd JW. (2005). Changes in phosphorylation of the NMDA receptor in the rat hippocampus induced by status epilepticus. J Neurochem 92, 1377-1385. O'Connell AD, Leng Q, Dong K, MacGregor GG, Giebisch G, Hebert SC. (2005). Phosphorylation-regulated endoplasmic reticulum retention signal in the renal outer-medullary K+ channel (ROMK). Proc Natl Acad Sci U S A 102, 9954-9959. Rao JS, Bazinet RP, Rapoport SI, Lee HJ. (2007). Chronic administration of carbamazepine down-regulates AP-2 DNA-binding activity and AP-2alpha protein expression in rat frontal cortex. Biol Psychiatry 61, 154-161. Reimann F, Ashcroft FM. (1999). Inwardly rectifying potassium channels. Curr Opin Cell Biol 11, 503-508. Rich DP, Berger HA, Cheng SH, Travis SM, Saxena M, Smith AE, Welsh MJ. (1993).Regulation of the cystic fibrosis transmembrane conductance regulator Cl- channel by negative charge in the R domain. J Biol Chem 268, 20259-20267. Roh S, Choi S, Lim I. (2007). Involvement of Protein Kinase A in Nitric Oxide Stimulating Effect on a BK(Ca) Channel of Human Dermal Fibroblasts. J Invest Dermatol Epub ahead of print Rossi P, Fillippi G, Armano S, Taglietti V, D’Angelo E. (1998). The weaver mutation causes a loss of inwar rectifier current regulation in premigratory granule cells of the mouse cerebellum. J Neuroscience. 18, 3537-3547. Rostock A, Tober C, Rundfelft C, Bartsch R, Engel J, Polymerpoulos EE, Kutsher B, Loscher W, Honack D, White HS, Wolf HH. A new anticonvulsant with broad spectrum activity in animal models of epileptic seizures. Epilepst Res 23, 211-223. Schulte U, Hahn H, Wiesinger H, Ruppersberg JP, Fakler B. (1998). pH-dependent gating of ROMK (Kir1.1) channels involves conformational changes in both N and C termini. J Biol Chem 273, 34575-34579. Schulte U, Fakler B. (2000). Gating of inward-rectifier K+ channels by intracellular pH. Eur J Biochem 267, 5837-5841. Schulze D, Krauter T, Fritzenschaft H, Soom M, Baukrowitz T. (2003). Phosphatidylinositol 4,5-bisphosphate (PIP2) modulation of ATP and pH sensitivity in Kir channels. A tale of an active and a silent PIP2 site in the N terminus. J Biol Chem 278, 10500-10505. Signorini S, Liao YJ, Duncan SA, Jan LY, Stoffel M. (1997). Normal cerebellar development but susceptibility to seizures in mice lacking G protein-coupled, inwardly rectifying K+ channel GIRK2. Proc Natl Acad Sci U S A 94, 923-927. Simon S. (2001). Pyrrolidone derivatives. The Lancet 358, 1885-1892. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, McHarg ML, Gagnon D, Rosales TO, Peiffer A, Anderson E, Lepper M. (1998). A novel potassium, channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nature Genetics 18, 25029. Smart SL, Lopantsev V, Zhang CL, Robbins CA, Wang H, Chiu SY, Schwartzkroin PA, Messing A, Tempel BL. (1998). Deletion of the K¬V¬1.1 potassium channel causes epilepsy in mice. Neuron 20, 809-819. Steinhauser C, Seifert G. (2002). Glial membrane channels and receptors in epilepsy: impact for generation and spread of seizure activity. Eur J Pharmacol 447, 227-237. Tong X., Patsalos PN. (2001). A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol 133, 867-874. Van Rooijen LA, Vadnal R, Dobard P, Bazan NG. (1986). Enhanced inositide turnover in brain during bicuculline-induced status epilepticus. Biochem Biophys Res Commun 136, 827-834. Wang H, Kunkel DD, Schwartzkwoin PA, Tempep BL. (1994). Localization of K¬V¬1.1, two K+ channel proteins, to synaptic terminals, somata, and dendrites in the mouse brain. J Neuroscience 14, 4588-4599. Wang HS, Pan Z, Shi W, Brown BS, Cohen IS, Dixon JE, McKinnon D. (1998). KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 282, 1890-1893. Wang W. (1997). Renal K+ channels: structure and function. Annu. Rev. Physiol 59, 413-436. Wang W. (1999). Regulation of the ROMK channel: interaction of the ROMK with associate proteins. Am J Physiol 277, F826-831. Wickenden AD. (2002). Potassium channels as anti-epileptic drug targets. Neuropharmacology 43, 1055-1060. Wilson EA, Brodie MJ. (1996). New antiepileptic drugs. Bailleres Clin Neurol 5, 723-747. Wu J, Xu H, Shen W, Jiang C. (2004). Expression and coexpression of CO2-sensitive Kir channels in brainstem neurons of rats. J Membr Biol 197, 179-191. Xie LH, John SA, Ribalet B, Weiss JN. (2007). Activation of inwardly rectifying potassium (Kir) channels by phosphatidylinosital-4,5-bisphosphate (PIP(2)): Interaction with other regulatory ligands. Prog Biophys Mol Biol 94, 320-335. Xiong ZQ, Saggau P, Stringer JL. (2000). Activity-dependent intracellular acidification correlates with the duration of seizure activity. J Neurosci 20, 1290-1296. Xu ZC, Yang Y, Hebert SC. (1996). Phosphorylation of the ATP-sensitive, inwardly rectifying K+ channel, ROMK, by cyclic AMP-dependent protein kinase. J Biol Chem 271, 9313-9319. Yamada K, Ji JJ, Yuan H, Miki T, Sato S, Horimoto N, Shimizu T, Seino S, Inagaki N. (2001). Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. Science 292, 1543-1546. Yanovsky Y, Misgeld U. (2003). Suppression of epileptiform activity by GABA¬B¬ receptors in wild type and weaver hippocampus in vitro. Epilepsy Res 52, 263-273. Yoshida S, Ikeda M, Busto R, Santiso M, Martinez E, Ginsberg MD. (1987). Cerebral phosphoinositide, triacylglycerol and energy metabolism during sustained seizures induced by bicuculline. Brain Res 412, 114-124. Zeng WZ, Liou HH, Krishna UM, Falck JR, Huang CL. (2002). Structural determinants and specificities for ROMK1-phosphoinositide interaction. Am J Physiol Renal Physiol 282, F826-834. Zeng WZ, Li XJ, Hilgemann DW, Huang CL. (2003). Protein kinase C inhibits ROMK1 channel activity via a phosphatidylinositol 4,5-bisphosphate-dependent mechanism. J Biol Chem 278, 16852-16856. Zhang YY, Sackin H, Palmer LG. (2006). Localization of the pH gate in Kir1.1 channels. Biophys J 91, 2901-2909. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/25073 | - |
dc.description.abstract | 新一代抗癲癇藥物Levetiracetam (LEV, Keppra, (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide)目前在臨床上用於治療partial-onset epileptic seizures。LEV可作用於電位依賴型鉀離子通道並減少動作電位頻率,故可降低神經興奮性。鉀離子通道可調控神經的興奮性,並且可為抗癲癇藥物作用的標的。ROMK1離子通道屬於內流型整流鉀離子通道的成員,密集分布於海馬迴,具有穩定膜電位的功能。
在本實驗中,我們使用蛙卵作為表達ROMK1離子通道蛋白質之表現載體,並使用inside-out膜片電位鉗定技術 (patch clamp)測量ROMK1離子通道所表達之電流。我們發現新一代抗癲癇藥物LEV可增加ROMK1離子通道所表達之電流,且其作用具有濃度依賴性,EC50=362.6μM。而目前已知ROMK1離子通道受PIP2、細胞內酸鹼度、以及蛋白質激酶A(cyclic AMP-dependent protein kinase, PKA)與蛋白質激酶C(protein kinase C, PKC)等胞內物質調控,因此我們利用以上已知的分子調控機制探討LEV活化ROMK1離子通道的可能機轉。 根據之前的研究,已確認扮演PIP2結合位點(Arg188)、PKA磷酸化位點(Ser44、Ser219、Ser313)及PKC磷酸化位點(Ser183、The191、Thr193、Ser201、Thr234)及pH sensor(Lys80)角色之特定胺基酸,我們分別將wild type以及各種點突變之ROMK1離子通道蛋白質表現在蛙卵細胞上,發現LEV可活化PIP2結合位點之突變R188Q、PKC磷酸化位點之突變S183A、T191A、T193A、S201A、T234A,以及對pH不敏感之突變K80M,顯示LEV與ROMK1離子通道交互作用的過程並不牽涉PIP2以及PKC磷酸化,亦與胞內酸鹼值無關。而對ROMK1離子通道投與PKA抑制劑H89可部分抑制LEV的作用,且LEV無法活化PKA磷酸化位點之突變S219A以及S313A,顯示LEV透過PKA相關路徑活化ROMK1離子通道。我們進一步利用單點突變方式將PKA磷酸化位點置換為帶負電荷之天門冬胺酸(Aspartic acid,D)以模擬受磷酸化而帶負電的情形,探討LEV是否透過電荷改變而活化ROMK1離子通道。而我們的研究結果顯示,將PKA磷酸化位點突變為帶負電之胺基酸,S219D及S313D仍然無法與LEV作用,顯示電荷的改變並不足以模擬wild type ROMK1離子通道受PKA磷酸化後可與LEV交互作用的狀態,顯示電荷並不是LEV與ROMK1離子通道交互作用的必須條件。而由細胞內面投予LEV可使ROMK1離子通道表達的電流增大,暗示著ROMK1離子通道上可能具有LEV的結合位點,因此我們推測,ROMK1離子通道受PKA磷酸化之後,其構型產生改變,而LEV恰好可與此構型交互作用,進而增強ROMK1離子通道表達之電流。 本實驗證明LEV可增加ROMK1離子通道表達之電流,活化ROMK1離子通道而促進神經細胞的過極化可能是LEV尚未被發現的抗癲癇的機轉之一。 | zh_TW |
dc.description.abstract | Levetiracetam (LEV, (-)-(S)-α-ethyl-2-oxo-1-pyrrolidine acetamide), a novel antiepileptic drug, is effective in the treatment of partial-onset epileptic seizures. It is reported that LEV exerts its antiepileptic effect by modulating voltage-dependent potassium channels to lower action potential frequency. Potassium channels regulate neuronal excitability, and serve as target of anticonvulsant. ROMK1 channels, a member of inwardly rectifying potassium channels, are abundant in hippocampus which is highly related to the generation of seizure activities. The effect of LEV on ROMK1 was studied by inside-out patch-clamp recording in xenopus oocyte expression system. LEV dose-dependently enhanced ROMK current with EC¬50¬ of 362.6μM. LEV also enhanced ROMK1 current in mutations of PIP¬2¬ binding sites, R188Q and K218A, indicating that PIP¬2 is not involved in the interaction between LEV and ROMK1 channels. Substitution of PKC phosphorylation sites, Ser183, The191, Thr193, Ser201¬¬, Thr234 for alanine did not abolish the effect of LEV, meaning that LEV does not activate ROMK1 through PKC phosphorylation-dependent pathway. K80M is pH-insensitive, and LEV enhanced K80M currents, indicating that intracellular pH is not involved in the process of LEV enhancing ROMK1 current. Otherwise, PKA inhibitor H89 partially reduced the effect of LEV, and LEV failed to enhance the current expressed by S219A and S313A, mutations of PKA phosphorylation sites, suggesting that LEV may enhance ROMK currents through PKA-related pathway. Furthermore, we substitute PKA phosphorylation sites for asparatate to investigate whether negative charge is required for LEV to enhance ROMK1 currents. LEV had no effect on S219D and S313D, indicating that negative charges are not necessary for LEV to activate ROMK1 channels. We speculate that PKA phosphorylation may offer an appropriate conformation for LEV. LEV applied to the intracellular surface of the excised patches is able to activate ROMK1 channels, suggesting that its binding site could be on the intracellular leaflet, and it may interact with phosphorylated ROMK1 channels and therefore amplify the currents. This study suggests that enhacing ROMK1 currents is one of the underlying mechanisms of LEV in the reduction of neuronal excitability. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T06:01:39Z (GMT). No. of bitstreams: 1 ntu-96-R94443020-1.pdf: 2688396 bytes, checksum: 72d0e9b4093f1efabed25c5b7f9756b5 (MD5) Previous issue date: 2007 | en |
dc.description.tableofcontents | 口試委員會審定書………………………………………………………………. i
誌謝……………………………………………………………………………….. ii 中文摘要…………………………………………………………………………. iii 英文摘要………………………………………………………………………….. v 第一章 導論……………………………………………………………………1 第二章 研究目的與動機………………………………………………………… 22 第三章 實驗材料與方法………………………………………………………24 第一節 實驗材料……………………………………………………………24 第二節 實驗方法……………………………………………………………27 第四章 實驗結果………………………………………………………………32 第一節 LEV可增加wild type ROMK1離子通道所表達之電流………32 第二節 胞內酸鹼度不參與LEV與ROMK1離子通道之交互作用……34 第三節 PIP2不參與LEV與ROMK1離子通道之交互作用………………36 第四節 PKC不參與LEV與ROMK1離子通道之交互作用………………38 第五節 PKA參與LEV與ROMK1離子通道之交互作用………………40 第五章 討論………………………………………………………………………43 圖表…………………………………………………………………………………58 參考文獻……………………………………………………………………………79 | |
dc.language.iso | zh-TW | |
dc.title | Levetiracetam對內流型整流鉀離子通道作用之探討 | zh_TW |
dc.title | Study on the effect of levetiracetam in Kir1.1 channels | en |
dc.type | Thesis | |
dc.date.schoolyear | 95-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 符文美,邱麗珠,郭鐘金 | |
dc.subject.keyword | 癲癇,鉀離子通道, | zh_TW |
dc.subject.keyword | anticonvulsant,K channels,Kir, | en |
dc.relation.page | 93 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2007-07-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-96-1.pdf 目前未授權公開取用 | 2.63 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。